600513 Jiangsu Lianhuan Pharmaceutical
- 8.84
- -0.20-2.21%
Jiangsu Lianhuan Pharmaceutical News
Lianhuan Pharmaceutical (600513.SH) will distribute 0.15 yuan per share in 2023. The stock registration date is May 23
Lianhuan Pharmaceutical (600513.SH) issued an announcement that the company will implement the 2023 annual equity distribution, distributed per share...
Lianhuan Pharma Obtains China Registration Approval for Antihistamine
Jiangsu Lianhuan Pharmaceutical (SHA:600513) obtained a drug registration certificate from China's National Medical Products Administration for its ebastine oral solution, according to a filing with t
Lianhuan Pharmaceutical (600513.SH) obtained the “Drug Registration Certificate” for evastine oral solution
Lianhuan Pharmaceutical (600513.SH) issued an announcement. The company recently received approval and issuance from the State Drug Administration...
Lianhuan Pharmaceutical (600513.SH): Request the shareholders' meeting to authorize matters relating to issuing shares to specific targets through simple procedures
Gelonghui, March 18 | Lianhuan Pharmaceutical (600513.SH) announced that the board of directors of the company requested the 2023 annual shareholders' meeting to authorize the board of directors to handle matters relating to issuing shares with total financing not exceeding RMB 300 million and not exceeding 20% of net assets at the end of the most recent year to specific targets. The authorization period is from the date of consideration and approval of the 2023 Annual General Meeting of Shareholders to the date of the 2024 Annual General Meeting of Shareholders.
Why Jiangsu Lianhuan Pharmaceutical's (SHSE:600513) Shaky Earnings Are Just The Beginning Of Its Problems
Jiangsu Lianhuan Pharmaceutical Co., Ltd.'s (SHSE:600513) recent weak earnings report didn't cause a big stock movement. We think that investors are worried about some weaknesses underlying the earni
Lianhuan Pharmaceutical (600513.SH): Net profit in 2023 fell 4.5% year-on-year, and plans to pay 10 to 1.5 yuan
On March 5, Ge Longhui Pharmaceutical (600513.SH) released its 2023 annual report. Operating revenue was 2.174 billion yuan, up 11.20% year on year, net profit of 135 million yuan, down 4.5% year on year, after deducting non-net profit of 116 million yuan, down 13.27% year on year, and basic earnings per share of 0.47 yuan. It is proposed to distribute a cash dividend of 1.5 yuan for every 10 shares to all shareholders.
Lianhuan Pharmaceutical (600513.SH): Recertified as a high-tech enterprise
Gelonghui, February 22丨Lianhuan Pharmaceutical (600513.SH) announced that the company recently received the “High-tech Enterprise Certificate” jointly issued by the Jiangsu Provincial Department of Science and Technology, the Jiangsu Provincial Department of Finance, and the Jiangsu Provincial Taxation Bureau of the State Administration of Taxation. Certificate number: GR202332009520, date of issue: December 13, 2023, validity period: three years. The company's current certification of a high-tech enterprise is a re-certification after the original certificate expires.
Lianhuan Pharmaceutical (600513.SH): Subsidiary re-certified as a high-tech enterprise
Gelonghui, Feb. 7: Lianhuan Pharmaceutical (600513.SH) announced that its subsidiaries Nanjing Lianzhi Pharmaceutical Technology Co., Ltd. and Chengdu Yazhong Biopharmaceutical Co., Ltd. have recently each received the “High-tech Enterprise Certificate”. The subsidiary's high-tech enterprise certification is a re-certification after the original certificate expires.
Lianhuan Pharmaceutical (600513.SH): Controlling shareholder increased shareholding by 1.31%
Gelonghui, Feb. 6丨Lianhuan Pharmaceutical (600513.SH) announced that the controlling shareholder of the company, Jiangsu Lianhuan Pharmaceutical Group Co., Ltd. (hereinafter referred to as “Lianhuan Group”) increased its holdings of the company's shares through centralized bidding transactions through the Shanghai Stock Exchange trading system on February 6, 2024, accounting for 1.31% of the company's total share capital.
Investors Don't See Light At End Of Jiangsu Lianhuan Pharmaceutical Co., Ltd.'s (SHSE:600513) Tunnel And Push Stock Down 28%
Jiangsu Lianhuan Pharmaceutical Co., Ltd. (SHSE:600513) shareholders won't be pleased to see that the share price has had a very rough month, dropping 28% and undoing the prior period's positive perfo
Jiangsu Lianhuan Pharmaceutical Co., Ltd. (SHSE:600513) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?
It is hard to get excited after looking at Jiangsu Lianhuan Pharmaceutical's (SHSE:600513) recent performance, when its stock has declined 23% over the past month. However, the company's fundamental
Lianhuan Pharmaceutical (600513.SH): Received a government subsidy of RMB 16.1515 million
Gelonghui, January 18, 丨 Lianhuan Pharmaceutical (600513.SH) announced that from January 1, 2023 to December 31, 2023, the company and its subsidiaries received a total of 16.1515 million yuan in government subsidies, including 14.236 million yuan in revenue-related government subsidies and 1.920,900 yuan in asset-related government subsidies.
Lianhuan Pharmaceutical (600513.SH) obtained the “Drug Registration Certificate” for temozolomide capsules
Lianhuan Pharmaceutical (600513.SH) issued an announcement. The company recently received the approval and issuance of temozolomide by the State Drug Administration...
Individual Investors Among Jiangsu Lianhuan Pharmaceutical Co., Ltd.'s (SHSE:600513) Largest Shareholders, Saw Gain in Holdings Value After Stock Jumped 14% Last Week
Key Insights Jiangsu Lianhuan Pharmaceutical's significant individual investors ownership suggests that the key decisions are influenced by shareholders from the larger public 47% of the business is
Lianhuan Pharma's Production Lines Pass GMP Inspection
Jiangsu Lianhuan Pharmaceutical's (SHA:600513) production lines passed the Good Manufacturing Practice inspection of the Food and Drug Administration of China's Jiangsu Province. The production lines
Lianhuan Pharmaceutical (600513.SH) received drug GMP compliance inspection results
Lianhuan Pharmaceutical (600513.SH) issued an announcement. Recently, the company learned from the Jiangsu Drug Administration website “...
Jiangsu Lianhuan Pharma Passes GMP Compliance Inspection
Jiangsu Lianhuan Pharmaceutical (SHA:600513) has passed a good manufacturing practice (GMP) compliance inspection for its active pharmaceutical ingredient production line, according to a filing on Thu
Lianhuan Pharmaceutical (600513.SH): Received drug GMP compliance test results
Gelonghui, October 18, 丨 Lianhuan Pharmaceutical (600513.SH) announced that the company learned the “Notice of Pharmaceutical GMP Conformity Inspection Results” from the website of the Jiangsu Drug Administration. According to the relevant provisions of the “Drug Administration Law” and “Pharmaceutical Production Supervision and Administration Measures”, Jiangsu Lianhuan Pharmaceutical Co., Ltd. was inspected and assessed for compliance with the “Pharmaceutical Production Quality Management Specification”, and the results met the requirements. This GMP compliance test for the API levonorgestrel is a GMP test for the new process after the change. There has been no new investment in the production line for the new process of the API levonorgestrel.
Jiangsu Lianhuan Pharma Gets Nod to Market Ingredient For Drug Against Addison's Disease
Jiangsu Lianhuan Pharmaceutical (SHA:600513) has obtained approval from China's National Medical Products Administration to market its fludrocortisone acetate chemical raw material. Fludrocortisone ac
Lianhuan Pharmaceutical (600513.SH) has received a total of 139 million yuan in relocation compensation
Lianhuan Pharmaceutical (600513.SH) issued an announcement. Previously, according to the company and the Yangzhou Bureau of Industry and Information Technology (Yuan Yang...
Analysis
Price Target
No Data
